Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYR-472 once-weekly add-on to insulin in type 2 diabetes (Phase 3)
jRCT2080222683Phase 3
- Sponsor
- Takeda
- Start
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing SYR-472 100 mg once weekly + insulin with Placebo once weekly + insulin (2 arms).
02
Drugs
trelagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT2080222683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222683.